Skip to content
Tablet Allopathic

Filgotin 200 mg tablet

Generic: Filgotinib Maleate

Company: Ziska Pharmaceuticals Ltd.. Prices are as listed on BestinMeds; your pharmacy price may differ.

Strength200 mg
PackStrip: 3600.00 taka

Reviewed by: not listed yet. Source: not listed yet.

Last updated November 16, 2025.

Compare

Same generic, same strength

Sorted by price per tablet. Ask your pharmacist before you switch brands.

Filgotinib Maleate 200 mg tablets

Prices as listed on BestinMeds.

1 brand listed
Filgotin (this medicine)450.00 taka per tablet

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250
Medicine guide

About this medicine

What this medicine is for, how to take it, and what to watch for.

Read the full Filgotinib Maleate guide

Indications

Rheumatoid arthritis: Filgotinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Filgotinib may be used as monotherapy or in combination with methotrexate (MTX). Ulcerative colitis: Filgotinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

Dosage and administration

Rheumatoid arthritis: The recommended dose of Filgotinib is 200 mg tablet once a day. Ulcerative colitis: The recommended dose of Filgotinib is 200 mg once daily. Patients who have not shown any therapeutic benefit after 22 weeks of treatment should discontinue Filgotinibib. In adults at higher risk of venous thromboembolism, major adverse cardiovascular events and malignancy, the recommended dose for maintenance treatment is 100 mg once daily. In case of flare of the disease, the dose may be escalated to 200 mg once daily. For long term treatment, the lowest effective dose should be used.

Side effects

The most frequently reported adverse reactions are nausea, upper respiratory tract infection (URTI), urinary tract infection (UTI), dizziness etc.

Precautions and warnings

Immunosuppressive medicinal products: Combination of filgotinib with other potent immunosuppressants such as azathioprine, ciclosporin, tacrolimus, biologic DMARDs (bDMARDs) or other Janus kinase (JAK) inhibitors is not recommended as a risk of additive immunosuppression cannot be excluded. Infections: Infections, including serious infections, have been reported in patients receiving filgotinib. The most frequent serious infection reported with filgotinib was pneumonia. Among opportunistic infections, TB, oesophageal candidiasis, and cryptococcosis were reported with filgotinib. Viral reactivation: Viral reactivation, including cases of herpes virus reactivation (e.g., herpes zoster), were reported in clinical studies. If a patient develops herpes zoster, filgotinib treatment should be temporarily interrupted until the episode resolves. Screening for viral hepatitis and monitoring for reactivation should be performed in accordance with clinical guidelines before starting and during treatment with filgotinib. Malignancy: The risk of malignancies is increased in patients with rheumatoid arthritis. Immunomodulatory medicinal products may increase the risk of malignancies. Fertility: In animal studies, decreased fertility, impaired spermatogenesis, and histopathological effects on male reproductive organs were observed. Vaccinations: Use of live vaccines during, or immediately prior to, filgotinib treatment is not recommended. Lipids: Treatment with filgotinib was associated with dose-dependent increase in lipid parameters, including total cholesterol, and high-density lipoprotein (HDL) levels, while low-density lipoprotein (LDL) levels were slightly increased. Venous thromboembolism: Consider the risks and benefits prior to treating patients with filgotinib, who may be at increased risk of thrombosis. Promptly evaluate patients with symptoms of thrombosis and treat appropriately.

Pregnancy and lactation

Use in Pregnancy: There are no or limited amount of data from the use of filgotinib in pregnant women. Studies in animals have shown reproductive toxicity. Based on findings in animals, filgotinib may cause fetal harm and is therefore contraindicated during pregnancy. Women of childbearing potential / Contraception: Women of childbearing potential have to use effective contraception during and for at least 1 week after cessation of filgotinib treatment. Lactation: It is unknown whether filgotinib is excreted in human milk. A risk to breastfed newborns/infants cannot be excluded. Therefore, filgotinib should not be used during breast-feeding.

Clinical details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250